Table 1

Patient and tumor characteristics

Patient no.AgeSexHistopathologyTNMSUV-FLT meanSUV-FLT maxKi-67 index
157FNSCLCT1N1M05.638.765%
253MNSCLCT2N1M04.02541%
377FNSCLCT2N1M03.985.343%
471FNSCLCT2N1M02.94.435%
575MNSCLCT2bN0M03.065.754%
653FNSCLCT2N1M0Neg.Neg.10%
761MNSCLCT3N0M04.896.845%
866MNSCLCT1N0M03.244.726%
976MNSCLCT4N2M03.055.235%
1055MNSCLCT2N2Mx3.885.640%
1162FNSCLCTxN0M02.263.310%
1255MNSCLCT1N1M01.111.312%
1351FNSCLCT2N2M13.646.1043%
1460MNSCLCT4N1M05.628.240%
1556FNSCLCT3N3M06.3810.470%
1667MNSCLC (carcinoma in situ)T1N0M0Neg.Neg.32%
1766MSCLCT4N2M01.692.420%
1850MNon-Hodgkin’s lymphomaT2N0M02.534.212%
1968MColorectal cancer, pulmonary metrTxN0M1Neg.Neg.12%
2051MRenal cell carcinoma, pulmonary metrTxN0M12.073.423%
2165MRenal cell carcinoma, pulmonary metrTxN0M11.321.910%
2237FOsteosarcoma, pulmonary metTxN0M10.81611%
2375MBronchiolitis-Neg.Neg.0%
2476M2×3 cm nodule, clinical course indicated benign lesion-Neg.Neg.0%
2551FTuberculoma-Neg.Neg.5%
2659MBronchiolitis-Neg.Neg.0%
2769MBronchiolitis-Neg.Neg.0%
2867M1×2 cm nodule, clinical course indicated benign lesion-Neg.Neg.0%
2955FFibroma-Neg.Neg.0%
3056MBronchopulmonary chondroma-Neg.Neg.0%